Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B

Background & Aims Nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB) patients reduces liver‐related mortality. However, long‐term outcomes after pegylated interferon (PEG‐IFN) therapy remain to be elucidated. Therefore, we aimed to investigate the long‐term effectiveness and clinic...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2021-02, Vol.41 (2), p.288-294
Main Authors: Lee, Soon Kyu, Kwon, Jung Hyun, Lee, Sung Won, Jang, Jeong Won, Nam, Heechul, Baik, Kyoung Won, Yoo, Sun Hong, Nam, Soon Woo, Sung, Pil Soo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew
Format: Article
Language:English
Subjects:
Cirrhosis
Deoxyribonucleic acid
DNA
Health services
Hepatitis
Hepatitis B
Hepatitis B e antigen
Hepatitis B surface antigen
hepatocellular carcinoma
Interferon
Liver
Liver cirrhosis
nucleos(t)ides
Patients
pegylated interferon
Seroconversion
sustained response
Therapy
Viremia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims Nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB) patients reduces liver‐related mortality. However, long‐term outcomes after pegylated interferon (PEG‐IFN) therapy remain to be elucidated. Therefore, we aimed to investigate the long‐term effectiveness and clinical outcomes of PEG‐IFN therapy. Methods A total of 190 patients treated with PEG‐IFN for CHB or compensated cirrhosis were consecutively enrolled between 2005 and 2014, and 122 patients who completed the treatment were analysed. The initial response was assessed at 6 months post‐treatment and defined as achieving both
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14701